Faculty of Dentistry, McGill University, Montreal, Quebec, Canada H3A 1A4.
Cancer Lett. 2012 Jan 28;314(2):176-84. doi: 10.1016/j.canlet.2011.09.026. Epub 2011 Sep 29.
Breast cancer metastasis to bone results in pain, pathological fractures and hypercalcemia. Activation of osteoclasts is critical for the formation of osteolytic lesions by metastasizing tumors. Although the potent drugs, zoledronic acid and Denosumab were introduced, the presence of resistant or intolerant cases necessitated the continued search of osteoclast-targeting treatments. Rapamycin acts through the mTOR pathway, which is important for osteoclast formation. Mouse mammary carcinoma 4T1 cells were injected into the tibia of balb/c mice. Rapamycin treatment significantly decreased the osteoclast population and osteolysis associated with experimental metastases. Our data indicate the benefit of rapamycin in treating metastases-associated osteolytic disease.
乳腺癌骨转移可导致疼痛、病理性骨折和高钙血症。破骨细胞的激活对于转移瘤形成溶骨性病变至关重要。尽管引入了唑来膦酸和地舒单抗等强效药物，但仍存在耐药或不耐受病例，因此需要继续寻找针对破骨细胞的治疗方法。雷帕霉素通过 mTOR 通路发挥作用，该通路对破骨细胞的形成很重要。将小鼠乳腺癌 4T1 细胞注入 balb/c 小鼠的胫骨中。雷帕霉素治疗显著减少了与实验性转移相关的破骨细胞群和溶骨性破坏。我们的数据表明雷帕霉素在治疗转移性骨溶解疾病方面具有益处。
